Highlighting the Success of Vorasidenib for IDH-mutant Glioma: Development History and Current Approaches
Time: 12:30 pm
day: Conference Day 2
Details:
- Presenting the history of vorasidenib’s clinical development and its success in slowing tumor progression in patients with IDH-mutant low grade gliomas
- Incorporating translational data to inform subsequent clinical trials for patients with recurrent IDH-mutant gliomas
- Developing vorasidenib for additional high-risk patients with IDH-mutant gliomas
